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IN-HOSPITAL AND LONG- 
TERM OUTCOME AFTER 
PORCINE TRICUSPID VALVE 
REPLACEMENT 
Porcine bioprostheses are often used for tricuspid valve replacement, yet the 
long-term outcome after this procedure is not weil documented. Therefore, the 
records of 129 patients undergoing tricuspid valve replacement with Carpentier- 
Edwards (n = 88) or Hancock (n = 41) prostheses between 1975 and 1993 were 
reviewed. The operation required a repeat median sternotomy in 66 of 129 (51%) 
patients, whereas 67 of 129 (52%) underwent double or triple valve replacement. 
Operative mortality was 14% (2/14) in patients undergoing first-time isolated 
tricuspid valve replacement and 27% (35/129) overall. Survival at 5, 10, and 14 years 
was 56% - 5%, 48% -+ 5%, and 31% ± 9%, and freedom from tricuspid reoperation 
at 5, 10, and 14 years was 96% ± 3%, 93% -- 4%, and 49% ± 17%. No valve 
thrombosis was observed. In this largest reported series of porcine bioprostheses in 
the tricuspid position, long-term freedom from valve-related events was excellent 
because of a low incidence of valve thrombosis and a valve durability of 13 to 15 
years in a population with limited life expectancy. (J TrIORAC CARDIOVASC SURG 
1995;109:877-84) 
Donald D. Glower, MD, William D. White, MPH, L. Richard Smith, PhD, 
W. Glenn Young, MD, H. Newland Oldham, MD, Walter G. Wolfe, MD, and 
James E. Lowe, MD, Durham, N.C. 
A lthough tricuspid valve replacement was initially performed with mechanical prostheses, 1 the rel- 
atively high incidence of thrombosis or pannus 
ingrowth with mechanical valves in the tricuspid 
position 24 has prompted the use of bioprostheses 
for tricuspid valve replacement over the past 15 
years. 6Increasing reports of structural degeneration 
of bioprostheses in the aortic and mitral positions 
has rejuvenated consideration of mechanical tricus- 
pid valves, 7 despite very little data demonstrating 
the long-term outcome from tricuspid valve replace- 
ment with porcine bioprostheses. 
A retrospective study was undertaken to define 
more clearly the clinical outcome from porcine 
tricuspid valve replacement, both in the hospital and 
over the long term, based on the experience at a 
single institution. 
Patients and methods 
Over the period from 1974 through 1993, 143 patients 
underwent tricuspid valve replacement at Duke University 
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Medical Center. Of these 143 patients, 11 received various 
mechanical prostheses, 3 received pericardial bioprosthe- 
ses, and 129 patients had porcine prostheses inserted in 
the tricuspid position. Because the numbers were small 
for patients receiving valves other than porcine biopros- 
theses, the current study was limited to those 129 patients 
undergoing porcine tricuspid valve replacement. Preoper- 
ative, in-hospital, and follow-up information was obtained 
by review of the medical record and/or contact with the 
patient or referring physician. Follow-up was complete to 
1991 in 119 of 129 (91%) patients with a mean follow-up 
of 4 + 5 years and maximum follow-up of 16 years. 
Survival and freedom from reoperation were computed by 
the technique of Kaplan and Meier. 80perative mortality 
was defined as any death occurring in the hospital or 
within 30 days after operation? The Cox proportional 
hazards model was used to detect hose factors signifi- 
cantly affecting survival or freedom from reoperation over
time. Logistic regression analysis was used to examine 
factors affecting operative mortality. 1° Those variables 
with univariable significance at the 0.1 level were tested 
for multivariable significance by forward and backward 
elimination. Kaplan-Meier survival curves were compared 
by the log rank test. 1° Kaplan-Meier estimates were given 
as mean + standard error, and all other data were 
presented as mean -+ standard eviation unless otherwise 
stated. 
Results 
The year of operation for patients undergoing 
porcine trieuspid valve replacement was evenly dis- 
tributed over the period 1974 to 1993 (Fig. 1). Of the 
129 patients undergoing tricuspid valve replacement 
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Fig. 1. Number of porcine tricuspid valve replacements performed at Duke University over the period 
1974 to 1993. 
Table I. Concurrentprocedures 
Patients 
No. % 
Mitral valve repair/replacement 45 34 
Mitral and aortic valve replacement 23 18 
Closure of atrial septal defect 13 10 
Aortic valve replacement 4 3 
Closure of ventricular septal defect 4 3 
Other 4 3 
None 36 28 
with porcine bioprostheses, 88 patients received a 
standard Carpentier-Edwards prosthesis (Baxter 
Healthcare Corp., Edwards Div., Santa Ana, Calif.), 
and 41 patients received a Hancock prosthesis 
(Johnson & Johnson Cardiovascular, King of Prus- 
sia, Pa.). The mean age was 53 _+ 16 years, and 88 of 
129 (68%) patients were female. The cause of 
tricuspid valvutar disease was rheumatic in 55 pa- 
tients (43%), degenerative in 35 (27%), endocarditis 
in 13 (10%), Ebstein's anomaly in 13 (10%), and 
other causes in 13 (10%). Class III or IV congestive 
heart failure was present in 113 of 129 (88%) 
patients, and 54 of 129 (42%) patients had other 
significant medical comorbidity. Chronic atrial fi- 
brillation was present in 66 of 129 (51%) patients. 
Cardiac catheterization demonstrated 3+ or 
greater tricuspid regurgitation in 85 patients, 20 
patients had moderate or severe tricuspid stenosis, 
and 9 patients had combined stenosis and regurgi- 
tation. Seventeen patients (13%) had 75% or 
greater stenosis of 1 or more coronary vessels, and 9 
patients had accessory atrioventricular conduction 
pathways. A prior median sternotomy had been 
performed in 66 of 129 (51%) patients, with the 
most frequent prior procedure being mitral valve 
repair or replacement i  36 of 129 (28%) patients. 
At the time of tricuspid valve replacement, 93 of 
129 (72%) patients underwent concurrent proce- 
dures (Table I). In combination with the procedures 
listed in Table I, concurrent coronary bypass graft- 
ing was performed in 7 patients, and 7 patients 
underwent concurrent division of accessory atrio- 
ventricular pathways. Double valve replacement was 
performed in 44 of 129 (34%) patients, and triple 
valve replacement was performed in 23 of 129 
(18%) patients. Operative mortality was 27% (35/ 
129) overall, 14% (2/14) in patients undergoing 
first-time, isolated tricuspid valve replacement, and 
19% (4/21) in patients undergoing repeat median 
sternotomy for isolated tricuspid valve r placement. 
According to logistic regression analysis, age, con- 
current mitral valve replacement, and increased 
class of congestive heart failure were univariable 
predictors of operative mortality. Of these variables, 
only age and concurrent mitral valve replacement 
were independent predictors of operative mortality. 
Mortality increased from 5 of 44 (11%) for age less 
than 50 years to 8of 29 (28%) for age 50 to 59 years 
and 22 of 56 (39%) for age more than 60 years. 
Concurrent mitral valve replacement increased oper- 
ative mortality from 18% _+ 5% to 35% _+ 6%, and 
isolated triple valve replacement i creased mortality to 
6 of 19 (32%). Of 86 discharged patients, 44 (51%) 
received warfarin, 20 (23%) received aspirin alone, 
and 22 (26%) received neither aspirin nor warfarin. 
Late survival was 56% _+ 5% at 5 years, 48% _+ 
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Fig. 2. Overall survival of patients undergoing tricuspid valve replacement. 
5% at 10 years, and 31% +_ 9% at 14 years (Fig. 2). 
The most common cause of death, both in the 
hospital and after discharge, was congestive heart 
failure (Table II). Univariable predictors of de- 
creased survival were increased age, increased 
class of congestive heart failure, and increased 
pulmonary artery systolic pressure. Of these vari- 
ables, the only independent predictors of de- 
creased survival were increased age (X 2 = 8.7,p = 
0.003, /3 = 0.045 _ 0.015) and increased class of 
congestive heart failure (X 2 = 6.1, p = 0.01,/3 = 
0.82 ± 0.33). Overall survival at 10 years was 
23% + 9% for patients older than 60 years, 57% 
+_ 11% for patients aged 50 to 59 years, and 68% 
-+ 9% for patients less than 50 years old (p < 
0.001) (Fig. 3). Survival at 10 years was 29% + 8% 
for patients with class IV symptoms before the 
operation and 65% _ 7% for patients with class 
III symptoms or less (p < 0.001) (Fig. 3). 
For those patients discharged alive, the indepen- 
dent predictors of decreased survival were prior 
median sternotomy (X 2 = 4.6,p = 0.03,/3 = 1.16 _+ 
0.54) and increased pulmonary artery systolic pres- 
sure (X 2 = 4.3, p = 0.03,/3 = 0.022 +_ 0.011). Prior 
median sternotomy decreased 10-year survival for 
hospital survivors from 78% + 7% to 43% _+ 10% 
(p = 0.03), and preoperative pulmonary artery 
systolic pressure greater than 50 mm Hg decreased 
10-year survival for hospital survivors from 70% _ 
9% to 51% + 15% (p = 0.02) (Fig. 4). 
Table II. Causes of death 
Patients 
No. % 
Congestive heart failure 31 47 
Infection 11 17 
Other noncardiac 9 14 
Unknown 7 11 
Hemorrhage 4 6 
Other cardiac 4 6 
Total 66 100 
Only 8 patients required subsequent ricuspid 
valve reoperation. Four porcine tricuspid valves 
were reoperated on (9, 11, 12, and 14 years after the 
operation) for structural deterioration of the tricus- 
pid prosthesis, 1 porcine tricuspid valve was re- 
placed after 1.7 years for pannus ingrowth, and 3 
porcine tricuspid valves were replaced at the time of 
reoperation for aortic valve disease (5, 11, and 13 
years after the operation). Mean age for these 8 
patients was 41 +_ 18 years (p = 0.02 versus patients 
not requiring tricuspid valve reoperation). Freedom 
from tricuspid valve reoperation was 96% _ 3% at 
5 years, 93% _+ 4% at 10 years, and 49% ± 17% at 
14 years (Fig. 5). Concurrent aortic valve replace- 
ment was the only predictor of decreased freedom 
from tricuspid valve reoperation (X 2 = 7.4,p < 0.02, 
/3 = 2.3 _ 0.8). Concurrent aortic valve replacement 
decreased 10-year freedom from tricuspid valve 
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Fig. 3. Effect of age (leftpanel) or preoperative N w York Heart Association congestive heart failure class 
(right panel) on overall survival after porcine tricuspid valve replacement. 
I 
N at Risk 47 31 27 19 17 9 1 I 
ol 47 24 17 11 5 2 
100 . . . . . . . . . . . .  : . . . . . . . . . . . . . . . . . . . . . . . . .  
ù- 8O 
• ->= 60 > 
¢/) 
40 
._e 
o. 20 
0 
2 ùot ùodo 
~ U=q-~ T ..... T /~ 
~5t tL 
Not [39 26 23 17 11 6 1 
Redo 
Redo 122 9 5 4 3 0 0 
PAS<50 
......... p~~~,/õi ....t !- ..... 
L. - -  
0 5 10 15 0 5 10 15 
Postoperative Time (Ye«rs) Postoperative Time (Years) 
PAS<50 
PAS>50 
Fig. 4. Effects of previous median sternotomy (redo) (leflpanel) or preoperative pulmonary artery systolic 
pressure (PAS, mm Hg) (fight panel) on survival of patients discharged after porcine tricuspid valve 
replacement. 
reoperation from 98% _+ 2% to 79% _ 14% (p < 
0.01) (Fig. 5). Five additional patients required 
subsequent cardiac operations other than tricuspid 
valve reoperation, and all 5 of these reoperations 
were replacement of mitral valves that had been 
operated on previously. Freedom from any cardiac 
reoperation was 91% + 4% at 5 years, 79% _+ 7% at 
10 years, and 40% _ 15% at 14 years. The only 
predictor of decreased freedom from any cardiac 
reoperation was concurrent aortic valve replace- 
ment (X 2 = 5.3, p < 0.02,/3 = 1.35 _+ 0.59), which 
decreased 10-year freedom from any cardiac reop- 
eration from 85% _+ 7% to 63% _+ 18% (p = 0.02). 
No cases of clinical pulmonary embolism, tricuspid 
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Fig. 5. Freedom from tricuspid valve reoperation after porcine tricuspid valve replacement (leflpanel) and 
the effect of concurrent aortic valve replacement (AVR) (right panel). 
valve thrombosis, or tricuspid valve endocarditis 
developed. 
Discussion 
Although outcome after trieuspid valve replace- 
ment is well described, most series have relatively 
small patient numbers and orten combine me¢han- 
ical, porcine, and other biologie valve prosthe- 
ses.4, 11-13 The current series of 129 por¢ine prosthe- 
ses in the tricuspid position exceeds previous reports 
of 45 to 58 por¢ine tricuspid prostheses 3' » and is 
approa¢hed only by the experience of 101 porcine 
trieuspid prostheses in the mixed series of McGrath 
and asso¢iates. 4 Because of small patient numbers, 
few studies have been able to examine the determi- 
nants of in-hospital mortality 4'12,13 or long-term 
survival 4, 12, 14 after tricuspid valve replacement. 
The significant operative mortality of 27% in the 
eurrent series is not unlike operative mortalities of 
11% to 37% reported for tricuspid valve replace- 
ment in recent series. 3-5' 12, 13, 15, 16 Incremental risk 
factors for early mortality in previous reports in- 
cluded peripheral edema, use of a Hancock prosthe- 
sis, functional disability, white race, high cardiotho- 
racic ratio, age, female gender, New York Heart 
Association class, tricuspid regurgitation, pulmo- 
nary dysfunction, and abnormal liver function 
tests)2, 13, 17 The increased operative mortality after 
tricuspid valve replacement relative to aortic or 
mitral valve replacement has been speculated to 
result from the high percentage ofconcurrent aortic 
or mitral valve operations 3' 4, 13, 1» and from the high 
number of patients with previous median sternoto- 
mies. 4 Right ventricular dysfunction has been pro- 
posed as a potential contributor to operative mor- 
tality after tricuspid valve replacement for tricuspid 
regurgitation, 4 yet difficulties assessing preoperative 
right ventricular function have prevented clarifica- 
tion of the inttuence of right ventricular dysfunction 
on operative mortality. An additional factor poten- 
tially contributing to operative mortality is that, 
early in the current series, tricuspid valve replace- 
ment instead of repair was reserved for high-risk 
patients with functional tricuspid regurgitation 
caused by severe biventricular failure and multival- 
vular heart disease. 
Long-term survival after tricuspid valve replace- 
ment has varied considerably. Ten-year survival has 
been reported to be between 36% and 71%, with 
most series finding long-term survival to be rela- 
tively poor as in the current series. 3-s' 11, 15,16 Long- 
term survival after tricuspid valve repair 4' 11, 12 or 
after mechanical tricuspid valve replacement 16 has 
in fact been quite similar to the survival reported 
after bioprosthetic tricuspid valve replacement. In 
all series, congestive heart failure and cardiomyop- 
athy were the most common causes of death after 
tricuspid valve replacement. 4' 11-13 Previous studies 
found that risk factors for late death included pre- 
operative dema, increased crossclamp time, high 
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pulmonary artery pressure, earlier date of opera- 
tion, larger tricuspid valve size, prior cardiac 
operation, age greater than 55 years, and advanced 
functional disability. 12' 14,17 The current study gener- 
ally concurred with prior studies in finding age, con- 
gestive heart failure class, pulmonary artery systolic 
pressure, and prior median sternotomy to decrease 
overall or long-term survival. 
Relatively few series provide data regarding long- 
term freedom from reoperation after tricuspid valve 
replacement.3, 4, 12 In the mixed series of tricuspid 
valve replacements that included bovine pericardial 
valves, McGrath and associates 17 found that free- 
dom from reoperation fell dramatically from 85 % + 
7% at 8 years to 65% _+ 8% at 10 years after valve 
replacement. On the other hand, Barratt-Boyes and 
colleagues 12found freedom from reoperation to be 
70% --- 10% at 10 years for homograft tricuspid 
valve replacement, and Guerra and coworkers 3 re- 
ported that freedom from structural deterioration i  
Hancock tricuspid bioprostheses was 78% - 10% at 
10 years and 68% -+ 13% at 14 years. The current 
study confirmed that freedom from reoperation was 
excellent 10 years after porcine tricuspid valve re- 
placement, with some deterioration after 10 years 
(see Fig. 5). The series of McGrath, 4 Barrett- 
Boyes, 12 and Guerra, 3and their associates all found 
that death before 10 years was significantly more 
likely than tricuspid valve reoperation at 10 years. 
Although tricuspid valve repair remains preferable 
to tricuspid valve replacement in patients with rep- 
arable valves, 4' 11, 12 freedom from reoperation has 
been similar between tricuspid valve repair and 
tricuspid valve replacement. 4' 12 In a comparison of 
tricuspid versus mitral versus aortic valve replace- 
ment with Carpentier-Edwards prostheses, everal 
authors noted that reoperation was less likely 3' is 
and that valve degeneration was less 19 for porcine 
valves in the tricuspid position than in mitral or 
aortic positions. The lower pressures on the right 
side of the heart have been speculated tocontribute 
to the relative durability of porcine prostheses in the 
tricuspid position. The current series demonstrated 
that, in patients undergoing porcine tricuspid valve 
replacement, the primary determinant of reopera- 
tion was concurrent aortic valve replacement, and 
reoperation for aortic or mitral valve disease was 
more likely than reoperation for tricuspid valve 
dysfunction. This result suggests that mechanical 
prostheses should be strongly considered for aortic 
or mitral valve replacement a the time of porcine 
tricuspid valve replacement. 
The incidence of other valve-related morbidity 
was extremely ow in this and other series of tricus- 
pid valve replacements with bioprostheses. 3-5' 15 No 
episodes of endocarditis, valvular thrombosis, or 
thromboembolism occurred in the current series 
despite frequent lack of anticoagulation. Thrombo- 
embolism from porcine prostheses occurred in only 
2 of 101 patients reported on by McGrath and 
colleagues. 4 Thus tricuspid valve reoperation was 
the primary source of tricuspid valve-related long- 
term morbidity after porcine tricuspid valve replace- 
ment, yet tricuspid valve reoperation occurred infre- 
quently in the population of patients receiving 
porcine tricuspid valve replacement. 
The current study does have limitations in evalu- 
ating the long-term outcome for porcine tricuspid 
valve replacement. Although this is the world's 
largest series of porcine tricuspid valve replace- 
ments, the relatively small numbers limited the 
ability to detect hose variables resulting in adverse 
outcome, especially the unusual adverse outcome of 
reoperation. As with all retrospective analyses, the 
comparability between patients in this series and 
others is not easy to quantify, although preoperative 
patient characteristics are probably among the most 
significant determinants of postoperative r sults. 
The present study does, however, provide insight 
into outcome after porcine tricuspid valve replace- 
ment. In this population, the durability of the por- 
cine tricuspid prosthesis clearly exceeded the life 
expectancy ofmost patients receiving tricuspid pros- 
theses. As a result, adverse outcomes of reoperation 
and other valve-related morbidity were unusual. The 
porcine bioprosthesis therefore was clearly a good 
choice for the patients in the present study, espe- 
cially for patients over 60 years old, with class IV 
symptoms, with prior median sternotomy, or with 
pulmonary artery systolic pressures greater than 50 
mm Hg. Caution should be used in generalizing this 
study to other patient subgroups, such as signifi- 
cantly ounger patients whose life expectancy might 
well exceed the durability of the porcine prosthesis 
in the tricuspid position, as suggested by the fact 
that patients requiring reoperation i  the current 
series were significantly ounger than those not 
needing reoperation. However, even in these 
younger patients, the likelihood of reoperation taust 
be weighed against he continuous risk of anticoag- 
ulant-related hemorrhage 2° and the troubling in- 
cidence of tricuspid valve thrombosis or pannus 
ingrowth with mechanical tricuspid valve replace- 
ment.Z, 16 In the small subset of young patients with 
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excellent life expectancy, the choice of a porcine 
versus mechanical prosthesis for tricuspid valve 
replacement will await better long-term data re- 
garding reoperation and valve-related complica- 
tions between 10 and 20 years after operation. 
The current study further suggests that, in pa- 
tients undergoing concurrent aortic or mitral 
valve replacement, strong consideration should be 
given to use of mechanical aortic or mitral pros- 
theses, because the likelihood of reoperation for 
aortic or mitral valve replacement was actually 
greater than the likelihood of replacement of a 
dysfunctional tricuspid prosthesis. Improved means 
to assess and follow right ventricular function may 
assist in decreasing mortality for patients needing 
tricuspid valve replacement. 
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Discuss ion 
Dr. Kent W. Jones (Salt Lake City, Utah). I would like to 
congratulate Dr. Glower and his associates from Duke on 
compiling and reporting the results of a large group of 
patients undergoing tricuspid valve replacement with a 
porcine prosthesis. This represents a very difficult group of 
patients to treat from a number of standpoints: whether 
anything operatively should be done with the tricuspid 
valve either soMy or in conjunction with repair or replace- 
ment of other valves, whether to repair or to replace the 
valve, and if the decision is made for replacement, what 
prosthesis to use. 
I have the following questions. Given the fact that the 
majority of reoperations were done in patients having had 
previous mitral valve operations, are you more aggressive 
with treatment of the tricuspid valve at the time of the 
initial mitral valve operation? 
Dr. Glower. That is a good point. This series extends 
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from 1975 to 1993, and our practice has changed over that 
period. At this point we do tend to be relatively aggressive 
with patients with severe tricuspid regurgitation, but de- 
cisions have to be made. In the case of moderate regur- 
gitation that we believe is functional because of a mitral 
valve lesion, we orten will leave patients with mild regur- 
gitation and find that they do well. The fact that a number 
of these patients had had previous mitral procedures i
reason for caution, however. For patients who have severe 
regurgitation attheir initial mitral valve operation, strong 
consideration should be given to either repair or replace- 
ment of the tricuspid valve. Also, many of the patients 
requiring reoperation for their tricuspid valve after a 
previous procednre had had rheumatic disease early in 
this series. These patients may have more native tricuspid 
valve disease than some of the other patients with other 
causes for regurgitation. 
Dr. Jones. I agree with that. All of us are being more 
aggressive and regarding the tricuspid valve as a second 
primary problem, not a problem resulting from the mitral 
valve disease. 
The mean age at operation of your patients was 53 
years, but there was a distinct dropoff in the curve 
documenting prosthesis durability in the period of 10 to 15 
years after the operation. The operative mortality for 
reoperation solely for tricuspid valve replacement was 
19%, and there was a significant increase in the operative 
mortality for patients older than age 60 years. Reports in 
the literature advocate the use of the St. Jude Medical 
prosthesis (St. Jude Medical, Inc., St. Paul, Minn.) in the 
tricuspid position as opposed to other mechanical pros- 
theses used in earlier reports. Do these facts change your 
choice of prosthesis, especially if aortic and/or mitral valve 
replacement with a mechanical prosthesis i  necessary? 
Dr. Glower. Other prostheses are available, such as the 
St. Jude Medical valve, that have not been available in 
rauch of the older data. Much of the limited literature 
regarding the use of mechanical valves for tricuspid valve 
replacement does relate to series from the late 1970s and 
early 1980s. Not much information concerning the St. 
Jude Medical prosthesis has been published. However, the 
potential risk of valve thrombosis, about 10% per patient- 
year or less, must be counterbalanced against he extra 
risk of having to reoperate and replace a porcine prosthe- 
sis in 10 to 15 years in a younger patient. That decision has 
to await more complete data on the risk of thrombosis 
over the long term with the St. Jude Medical valve in the 
tricuspid position. It is also contingent on making a 
reasonable stimation of survival in these patients. A1- 
though many of them were young, the patients in this 
series tended to have end-stage heart disease. Their 
chance for survival was not good because of advanced 
rheumatic ardiac disease. 
Dr. Jones. Only 51% of your patients receive postoper- 
ative anticoagulation. What is your indication for antico- 
agulation? 
Dr. Glower. Our current indications are the same as 
those in most institutions. Patients with a mitral prosthesis 
and atrial fibrillation are given anticoagulants. Any patient 
with a mechanical prosthesis is given anticoagulants. In
this series, that includes half of the patients at the time of 
discharge. At latest follow-up, about three quarters of 
these patients ultimately were receiving anticoagulation. 
The porcine prosthesis may or may not avoid the need for 
anticoagulation, but the major reason for choosing this 
valve over the mechanical prosthesis was to avoid the risk 
of tricuspid thrombosis. 
Dr. Jones. Even in patients who lack atrial ventricular 
synchrony, if they have only a tricuspid prosthesis n place, 
you do not anticoagulate? 
Dr. Glower. We do not. In fact, we have traditionally 
prescribed aspirin alone for the majority of them and have 
had very good results with that. 
Dr. Jones. My last question has three parts, but they all 
intertwine. 
You did not address morbidity, significantly and specif- 
ically heart block, which is a significant potential morbid- 
ity problem with the tricuspid valve and can lead to an 
increase in mortality. What percentage of your patients 
had heart block that resulted from the operation? Do you 
place a permanent epicardial electrode at the time of 
tricuspid valve repair or specifically replacement? If you 
need to use a pacemaker system after the operation, do 
you use an epicardial system or do you use an endocardial 
electrode through the tricuspid prosthesis? 
Dr. Glower. You bring up a small subset of these 
patients who are difficult to manage. In this series of about 
129 patients, five required placement of a pacemaker after 
the operation. However, three of those had a ventricular 
pacing wire in place preoperatively that had to be re- 
moved so that the tricuspid valve could be replaced. Two 
patients required a new pacemaker postoperatively for 
heart block that they did not have before the operation. 
This is a small number of patients, and our experience is
not large. In one patient we were actually able to leave the 
preoperative pacemaker wire in place and put the valve in 
around that. Out first choice is to use temporary wires for 
the vast majority of patients in the absence of heart block. 
If we detect heart block in the operating room, we strongly 
consider putting permanent epicardial wires on the pa- 
tient after the operation. That has probably been done 
about half the time. Our cardiologists also have had 
relatively good success in a small number of patients in 
placing ventricular wires through the tricuspid prosthesis 
after the operation as necessary. If the patient is in the 
operating room with complete heart block and tricuspid 
valve replacement, our first choice is to put at least some 
epicardial wires on and have that as an option. 
